Journal
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
Volume 42, Issue 2, Pages 300-306Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/0300060513505268
Keywords
Ovarian cancer; ovarian epithelial carcinoma; Cysteine-rich; angiogenic inducer; 61 (CYR61); immunohistochemistry
Funding
- Health Bureau of Jilin [2012Z019]
Ask authors/readers for more resources
Objective Cysteine-rich, angiogenic inducer, 61 (CYR61) is a key gene in the transforming growth factor- signalling pathway, which is involved in the development of many tumour types. This study aimed to clarify the status and clinical significance of CYR61 expression in patients with ovarian epithelial carcinoma. Methods Tissue from patients with ovarian epithelial carcinoma or benign ovarian tumours were investigated retrospectively for CYR61 expression at mRNA and protein levels, using reverse transcription-polymerase chain reaction and immunohistochemistry, respectively. Correlations between immunohistochemical scores and several clinicopathological parameters were investigated. Results In 50 patients with ovarian epithelial carcinoma and 50 patients with benign ovarian tumours, CYR61 expression on mRNA and protein levels was significantly higher in ovarian epithelial carcinoma tissue than in benign ovarian tissue. CYR61 expression was associated with regional lymph node metastases and progression of clinical disease stage. There was no difference in CYR61 expression between patients aged <50 years and 50 years. ConclusionsCYR61 expression was significantly upregulated in ovarian carcinoma tissue compared with benign ovarian tumour tissue samples. Protein CYR61 levels were associated with lymph node metastases and Union for International Cancer Control stage. Protein CYR61 may be useful in targeted diagnosis and therapy, for patients with ovarian epithelial carcinoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available